Pharmaceutical Product Development News

C. Ronald Bilowith, 71, of Ocean View, formerly of Clifton, N.J., died Sunday, Nov.

Sydney, NSW, November 20, 2009 -- Pharmaceutical wholesaler Leopold Fiebig has now fully implemented the IBS Pharma for its industry-specific, highly customized financial accounting processes which, as a result, are now completely integrated with the entire business.

In late October, when PPD, Inc. acquired fellow CRO Excel PharmaStudies, we suggested more CRO consolidation might follow.

PPD Inc. said Tuesday that it has signed a deal with Belgian drug-maker Janssen Pharmaceutica N.V. to take two developmental compounds through Phase II trials and possibly to market.

Drug development contractor Pharmaceutical Product Development Inc. said Wednesday it will buy BioDuro LLC in a move to expand capabilities in China.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome and the other to treat complicated skin and skin structure and respiratory infections.

Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

I've been critical of pharma's claims that developing countries are going to save them from the inevitable patent cliffs.

PPD, Inc. today announced its board of directors declared a cash dividend for the fourth quarter of 2009 under its annual cash dividend policy.

Takeda Pharmaceutical Co., Asia's biggest drugmaker, sued Teva Pharmaceutical Industries Ltd., alleging infringement of a U.S. patent for the insomnia treatment Rozerem.

PPD, Inc. today announced it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China.

Is consolidation the new theme in China's fragmented CRO sector? Over the past five to ten years, an almost bewildering array of new CROs has sprung into existence.

Pharmaceutical Product Development plans to spin off its drug development business and capitalize it with $100 million.

PPD, Inc. announced it has reached an agreement to acquire Excel PharmaStudies, Inc., a China-based CRO specializing in Phase II-IV clinical trials.

Get the latest news alerts: Follow LTW at Twitter. Local Tech Wire WILMINGTON, N.C. How effective is the Food and Drug Administration's system for monitoring adverse reactions to products? Pharmaceutical Product Development has won a $2.7 million contract to measure the effectiveness of the post-market surveillance system operated by the FDA's ...

PPD, Inc. today announced it has signed an agreement to invest $100 million in Celtic Therapeutics Holdings L.P., an investment partnership organized for the purpose of identifying, acquiring and investing in a diversified portfolio of 10 to 15 novel therapeutic product candidates.

PPD, Inc. today announced its board of directors has authorized management to proceed with preparations to spin off its compound partnering : business from its core contract research organization, or CRO, business.

PPD, Inc. today announced it has entered into an agreement to acquire Excel PharmaStudies, Inc.

PPD, Inc. today announced it has been awarded a contract by the U.S. Food and Drug Administration to evaluate the agencya s Center for Drug Evaluation and Research post-market spontaneous adverse event surveillance system.